Mangione William, Falls Zackary, Samudrala Ram
Jacobs School of Medicine and Biomedical Sciences, Department of Biomedical Informatics, University at Buffalo, Buffalo, NY, United States.
Front Pharmacol. 2023 Apr 26;14:1113007. doi: 10.3389/fphar.2023.1113007. eCollection 2023.
The two most common reasons for attrition in therapeutic clinical trials are efficacy and safety. We integrated heterogeneous data to create a human interactome network to comprehensively describe drug behavior in biological systems, with the goal of accurate therapeutic candidate generation. The Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun multiscale therapeutic discovery, repurposing, and design was enhanced by integrating drug side effects, protein pathways, protein-protein interactions, protein-disease associations, and the Gene Ontology, and complemented with its existing drug/compound, protein, and indication libraries. These integrated networks were reduced to a "multiscale interactomic signature" for each compound that describe its functional behavior as vectors of real values. These signatures are then used for relating compounds to each other with the hypothesis that similar signatures yield similar behavior. Our results indicated that there is significant biological information captured within our networks (particularly via side effects) which enhance the performance of our platform, as evaluated by performing all-against-all leave-one-out drug-indication association benchmarking as well as generating novel drug candidates for colon cancer and migraine disorders corroborated via literature search. Further, drug impacts on pathways derived from computed compound-protein interaction scores served as the features for a random forest machine learning model trained to predict drug-indication associations, with applications to mental disorders and cancer metastasis highlighted. This interactomic pipeline highlights the ability of Computational Analysis of Novel Drug Opportunities to accurately relate drugs in a multitarget and multiscale context, particularly for generating putative drug candidates using the information gleaned from indirect data such as side effect profiles and protein pathway information.
治疗性临床试验中药物淘汰的两个最常见原因是疗效和安全性。我们整合了异质数据以创建一个人类相互作用组网络,以全面描述生物系统中的药物行为,目标是准确生成治疗候选药物。通过整合药物副作用、蛋白质途径、蛋白质-蛋白质相互作用、蛋白质-疾病关联和基因本体,增强了用于散弹枪多尺度治疗发现、重新利用和设计的新药机会计算分析(CANDO)平台,并辅以其现有的药物/化合物、蛋白质和适应症库。这些整合网络被简化为每个化合物的“多尺度相互作用组特征”,将其功能行为描述为实值向量。然后使用这些特征将化合物相互关联,假设相似的特征会产生相似的行为。我们的结果表明,我们的网络中捕获了大量生物信息(特别是通过副作用),这提高了我们平台的性能,这是通过进行全对全留一法药物-适应症关联基准测试以及通过文献检索证实为结肠癌和偏头痛疾病生成新的候选药物来评估的。此外,药物对源自计算的化合物-蛋白质相互作用分数的途径的影响用作训练用于预测药物-适应症关联的随机森林机器学习模型的特征,突出了其在精神障碍和癌症转移方面的应用。这种相互作用组流程突出了新药机会计算分析在多靶点和多尺度背景下准确关联药物的能力,特别是利用从副作用谱和蛋白质途径信息等间接数据中收集的信息来生成推定的候选药物。